|
作用机制HSP70 heat-shock proteins抑制剂 |
|
|
|
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105 Following Oral Administration in Healthy and Hemodialysis Subjects
The purpose of the study is to evaluate the safety, tolerability, and PK following single and multiple ascending dose administration of VS-105 in healthy subjects and patients with chronic kidney disease stage 5D (CKD-5D) on hemodialysis.
100 项与 Vidasym, Inc. 相关的临床结果
0 项与 Vidasym, Inc. 相关的专利(医药)
100 项与 Vidasym, Inc. 相关的药物交易
100 项与 Vidasym, Inc. 相关的转化医学